Endocrine aspects of bone metastases

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 6, 2014, Pages 500-512

  Hofbauer, Lorenz C ^a,b   Rachner, Tilman D ^a   Coleman, Robert E ^c   Jakob, Franz ^d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d Stem Cell Division   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; NEW DRUG; OSTEOCLAST DIFFERENTIATION FACTOR; RADIUM CHLORIDE RA 223; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SEX HORMONE; VITAMIN D;

BONE METABOLISM; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER PREVENTION; CELL FUNCTION; CELL INTERACTION; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOCRINE SYSTEM; EPITHELIAL MESENCHYMAL TRANSITION; HORMONE ACTION; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MORBIDITY; MULTIPLE MYELOMA; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOCLAST; OSTEOLYSIS; OSTEOTROPISM; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; BONE TUMOR; BREAST TUMOR; DEFICIENCY; MALE; METABOLISM; OSTEOSCLEROSIS; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

BONE NEOPLASMS; BREAST NEOPLASMS; GONADAL STEROID HORMONES; HUMANS; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK;

EID: 84901626754     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70203-1     Document Type: Review

References (108)

1. Bleyer A, Welch HG Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012, 367:1998-2005.
2. Crawford S Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol 2013, 4:68.
3. Poon M, Zeng L, Zhang L, et al. Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents. Clin Oncol (R Coll Radiol) 2013, 25:435-444.
4. Melton LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005, 20:487-493.
5. Roodman GD Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
6. Weilbaecher KN, Guise TA, McCauley LK Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
7. Rachner TD, Khosla S, Hofbauer LC Osteoporosis: now and the future. Lancet 2011, 377:1276-1287.
8. Gavriatopoulou M, Dimopoulos MA, Christoulas D, et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009, 13:839-848.
9. Fields SZ, Parshad S, Anne M, et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs 2013, 22:87-101.
10. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
11. Bonewald LF The amazing osteocyte. J Bone Miner Res 2011, 26:229-238.
12. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011, 17:1231-1234.
13. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223. the ATAC Trialists' group.
14. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
15. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755. the Denosumab HALT Prostate Cancer Study Group.
16. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
17. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. the American Society of Clinical Oncology.
18. Khosla S, Oursler MJ, Monroe DG Estrogen and the skeleton. Trends Endocrinol Metab 2012, 23:576-581.
19. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
20. Jeong JH, Jung YK, Kim HJ, et al. The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues. Mol Cell Biol 2010, 30:2365-2375.
21. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998, 339:733-738. the Study of Osteoporotic Fractures Research Group.
22. Kollet O, Dar A, Shivtiel S, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006, 12:657-664.
23. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. the Writing Group for the Women's Health Initiative Investigators.
24. Beral V Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427. the Million Women Study Collaborators.
25. Taylor HS, Manson JE Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011, 96:255-264.
26. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657. the WHI Investigators.
27. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011, 305:1305-1314. the WHI Investigators.
28. Aldaz CM, Liao QY, LaBate M, Johnston DA Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996, 17:2069-2072.
29. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
30. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
31. Holmberg L, Anderson H HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004, 363:453-455. the HABITS steering and data monitoring committees.
32. Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013, 49:52-59.
33. Yu C, Shiozawa Y, Taichman RS, McCauley LK, Pienta K, Keller E Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr 2012, 22:131-148.
34. Roddam AW, Allen NE, Appleby P, Key TJ Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008, 100:170-183. the Endogenous Hormones and Prostate Cancer Collaborative Group.
35. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006, 106:1708-1714. the CaPSURE Investigators.
36. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003, 95:981-989.
37. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006, 91:3850-3856.
38. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148. the COU-AA-302 Investigators.
39. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. the AFFIRM Investigators.
40. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106:1553-1560.
41. Sun Y, Wang BE, Leong KG, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012, 72:527-536.
42. Morgentaler A Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol 2013, 189(suppl):S26-S33.
43. Skinner HG, Schwartz GG The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study. Cancer Epidemiol Biomarkers Prev 2009, 18:2869-2873.
44. Ooi LL, Zhou H, Kalak R, et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res 2010, 70:1835-1844.
45. Zheng Y, Zhou H, Ooi LL, Snir AD, Dunstan CR, Seibel MJ Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 2011, 71:1012-1021.
46. Sola B, Renoir JM Estrogenic or antiestrogenic therapies for multiple myeloma?. Mol Cancer 2007, 6:59.
47. Li Q, Yu K, Tian X, et al. 17β-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro. Leuk Res 2009, 33:1266-1271.
48. Li W, Frame LT, Hoo KA, Li Y, D'Cunha N, Cobos E Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro. Leuk Lymphoma 2011, 52:2380-2390.
49. He H, Chen L, Zhai M, Chen JZ Genistein down-regulates the constitutive activation of nuclear factor-kappaB in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Phytother Res 2009, 23:868-873.
50. Harikumar KB, Sung B, Tharakan ST, et al. Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res 2010, 8:751-761.
51. Ozdemir F, Esen N, Ovali E, et al. Effects of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma cells. Chemotherapy 2004, 50:190-193.
52. Johnson CS, Muindi JR, Hershberger PA, Trump DL The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res 2006, 26:2543-2549.
53. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008, 142:492-494.
54. Diamond T, Golombick T, Manoharan A Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol 2010, 85:302-303.
55. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
56. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008, 68:92-104.
57. Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011, 6:e19234.
58. Coleman RE, Rubens RD The clinical course of bone metastases from breast cancer. Br J Cancer 1987, 55:61-66.
59. Brunn Rasmussen B, Kamby C Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 1989, 185:856-859.
60. Zheng H, Kang Y Multilayer control of the EMT master regulators. Oncogene 2013, published online April 22. 10.1038/onc.2013.128.
61. Chimge NO, Baniwal SK, Luo J, et al. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 2012, 18:901-911.
62. Guttilla IK, Adams BD, White BAER ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab 2012, 23:73-82.
63. Matuszak EA, Kyprianou N Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Rev Endocrinol Metab 2011, 6:469-482.
64. Park SI, Liao J, Berry JE, et al. Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res 2012, 72:2522-2532.
65. Hofbauer LC, Schoppet M Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
66. Liao J, Schneider A, Datta NS, McCauley LK Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006, 66:9065-9073.
67. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 2000, 141:4357-4364.
68. Derynck R, Akhurst RJ, Balmain A TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129.
69. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
70. Brunetti G, Oranger A, Mori G, et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann NY Acad Sci 2011, 1237:19-23.
71. Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 2011, 1:e27.
72. Kristensen IB, Christensen JH, Lyng MB, et al. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leuk Lymphoma 2013, published online Aug 5. 10.3109/10428194.2013.820288.
73. Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2012, 131:1466-1471.
74. Ogawa Y, Schmidt DK, Nathan RM, et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem 1992, 267:14233-14237.
75. Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 1999, 75:206-214.
76. Eijken M, Swagemakers S, Koedam M, et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007, 21:2949-2960.
77. Hofland J, van Weerden WM, Steenbergen J, Dits NF, Jenster G, de Jong FH Activin A stimulates AKR1C3 expression and growth in human prostate cancer. Endocrinology 2012, 153:5726-5734.
78. Nomura M, Tanaka K, Wang L, et al. Activin type IB receptor signaling in prostate cancer cells promotes lymph node metastasis in a xenograft model. Biochem Biophys Res Commun 2013, 430:340-346.
79. Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006, 23:117-122.
80. Clézardin P Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 2011, 13:207.
81. Voorzanger-Rousselot N, Goehrig D, Journe F, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97:964-970.
82. Hall CL, Keller ET The role of Wnts in bone metastases. Cancer Metastasis Rev 2006, 25:551-558.
83. Yin JJ, Mohammad KS, Käkönen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100:10954-10959.
84. Alves RD, Eijken M, Bezstarosti K, Demmers JA, van Leeuwen JP Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production. Mol Cell Proteomics 2013, 12:2890-2900.
85. Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010, 107:5124-5129.
86. Young RJ, Coleman RE Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol 2013, 9:633-643.
87. Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100:36-43.
88. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221-1228.
89. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
90. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
91. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
92. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691. the ABCSG-12 Trial Investigators.
93. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405. the AZURE Investigators.
94. Coleman RE, Rathbone E, Brown JE Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013, 9:365-374.
95. Paterson AH, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012, 13:734-742.
96. Valachis A, Polyzos NP, Coleman RE, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013, 18:353-361.
97. Wilson C, Holen I, Coleman RE Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012, 38:877-889.
98. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828. the Austrian Breast and Colorectal Cancer Study Group.
99. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013, 24:398-405.
100. Schulman C, Irani J, Aapro M Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. BJU Int 2012, 109(suppl 6):13-21.
101. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012, 5. CD003188.
102. Melton LJ, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004, 19:25-30.
103. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008, 113:1588-1595. the GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network.
104. D'Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011, 52:771-775. the Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto), the Multiple Myeloma Working Partythe Multiple Myeloma Working Party, the Gisl (Gruppo Italiano Studio Linfomi) Cooperative Groupthe Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group.
105. Berenson JR, Yellin O, Boccia RV, et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res 2008, 14:6289-6295.
106. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21:679-689.
107. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113:2478-2487. the Atrasentan Phase 3 Study Group.
108. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223. the ALSYMPCA Investigators.